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EDITORIAL

Transforming Growth Factor-b in Thoracic Aortic Aneurysms: Good,
Bad, or Irrelevant?
Alan Daugherty, PhD, DSc; Zheying Chen, BS; Hisashi Sawada, MD, PhD; Debra L. Rateri, BS; Mary B. Sheppard, MD
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arfan syndrome is a multisystem disorder, but its most
devastating manifestations are aortic aneurysms and
dissection. This syndrome results from mutations in FBN1,
which encodes ﬁbrillin-1, a microﬁbrillar protein that decorates the surface of elastin ﬁbers.1,2 Over 100 known
mutations in FBN1 cause Marfan syndrome, resulting in a
wide variance of clinical presentations in affected individuals.3
While the genetic etiology of this disease is known, the
mechanism explaining how these mutations promote a focal
defect in the aorta has not been deﬁned. One proposed
hypothesis is through the intermediary role of a cytokine,
transforming growth factor b (TGF-b).4 A publication in this
issue of JAHA addresses the complex roles of TGF-b in
development of experimental aortopathies.5
TGF-b is secreted in a latent form as a complex that
includes the cytokine, a latency-associated peptide, and 1
of 3 members of the latent TGF-b binding protein (LTBP)
family. This complex retains TGF-b in an inactive form by
binding to extracellular matrix elements, including ﬁbrillin-1.
It has been proposed that ﬁbrillin-1 mutants associated
with Marfan syndrome reduce the binding of this complex
to facilitate release of bioactive TGF-b. TGF-b has 3
isoforms that are sequentially numbered. While increased
total TGF-b1 protein has been detected in tissue surgically
removed from individuals with aortopathies, there was no
detected increase of bioactive TGF-b1, as deﬁned by the
presence of the 25 kDa form. TGF-b2 and 3 were detected
in minimal amounts.6 Although increased bioactive TGF-b
has not been detected in Marfan syndrome–induced
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aortopathy, evidence for increased activity of this cytokine
has been inferred from increased presence of mediators of
intracellular signaling, primarily the phosphorylated form of
SMAD2 (pSmad2). Indirect evidence supporting the role of
excessive TGF-b in promoting aortopathies is that downregulation of LTBP3 attenuated disease and was associated
with decreased abundance of pSmad2.7 More directly, a
seminal publication demonstrated reduced dilation of the
ascending aorta in ﬁbrillin-1 haploinsufﬁcient mice following
administration of an antibody that neutralized activity of all
TGF-b isoforms.8 Neutralization of TGF-b also reduced
aortic size in hypercholesterolemic mice with CXCL10
deﬁciency during chronic angiotensin II infusion.9 Profound
TGF-b neutralization using the mouse monoclonal antibody,
1D11, also improved survival in ﬁbrillin-1 hypomorphic
mice.10
While these early studies present a case for inhibition of
TGF-b being a therapeutic strategy, evolving literature has
painted a more confusing landscape for the role of TGF-b in
aortopathies.11,12 This includes studies in which manipulation
of TGF-b activity provided diametrically opposing data:
increased TGF-b is protective against aortopathies. These
studies have either administered TGF-b neutralizing antibodies or genetically manipulated TGF-b and its receptors to
attenuate physiological function.
Several studies have determined the effect of neutralizing
TGF-b antibodies on experimental aortopathies with variable
results. Some studies have demonstrated that administration
of TGF-b antibodies had no effect on AngII-induced aortic
dilation during profound neutralization.13 Conversely, profound TGF-b neutralization has been demonstrated to
increase aortic rupture rates and aneurysmal expansion in
both ﬁbrillin-1 hypomorphic mice and those chronically
infused with AngII.10,13,14 These studies reported increased
incidence of aortic dissection and rupture in both abdominal
and thoracic regions.
The role of TGF-b deﬁciency has also been studied, but the
low postnatal viability of mice deﬁcient in its different
isoforms is a barrier to deﬁning the effect on aortic diseases.
One study has demonstrated augmented aortic root aneurysms in both TGF-b2 heterozygous deﬁcient and ﬁbrillin-1
haploinsufﬁcient mice.15 Although these mice demonstrated
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studies determined the abundance of pSmad2 in aortic tissue
extracted from 12-month-old mice with extensive aortic
disease. Use of diseased tissue makes it impossible to
determine whether changes in protein abundance are a cause
or consequence of the diseases. Hence, the approach used by
Wei et al5 lends great credibility to the concept that TGF-b
signaling is reduced in the formative stage of aortopathies in
ﬁbrillin-1 haploinsufﬁcient mice.
In a previous study from Dichek’s laboratory,21 deletion of
TGF-bR2 led to aortic pathologies of thickened media and
expanded aortic lumen. This pathology extended beyond the
ascending aorta and into the descending and suprarenal aorta.
To provide insight into the effect of smooth muscle cell–
speciﬁc TGF-bR2 in Marfan aortopathies, these receptors were
deleted in mice that were halpoinsufﬁcient for ﬁbrillin-1. As
with deleting TGF-bR2 in mice with normal expression of
ﬁbrillin-1, deletion of this receptor in ﬁbrillin-1 haplosufﬁcient
mice also augmented aortic pathology. Overall, this study
provides further evidence that challenges the dogma stating
that TGF-b overactivity is the cause of Marfan-associated aortic
disease.
Collectively, the profound aortopathies found in TGF-b and
TGF-bR manipulated mice demonstrate the critical need for
further studies on the role of this cytokine and its receptors.
The wide range of disparate opinions on whether TGF-b is
harmful or helpful in aortopathies needs to be resolved by
careful experimental design and objective interpretation. For
example, use of pSmad2 as a surrogate marker of TGF-b
signaling has caveats such as its lack of exclusivity. The
approach of immunostaining pSmad2 also requires careful
application of controls to demonstrate that tissue staining is
speciﬁc. Furthermore, as described by Wei et al,5 rigorous
and reproducible ultrasonic measurement of aortic diameter
is needed for meaningful interpretation into mechanisms.
Within the context of the current literature, the
publication of Wei et al5 provides further evidence that TGF-b is
predominantly a protective cytokine against development of
thoracic aortic disease. The effects of TGF-b on thoracic
aortic aneurysms has been mechanistically linked to angiotensin II.11 This link is based on evidence of angiotensin II
both augmenting TGF-b secretion and stimulating the same
intracellular signaling pathways. However, unlike the variable
effects of TGF-b neutralization on experimental thoracic aortic
disease, there is impressive consistency of angiotensin
receptor antagonism in attenuating aortic dilation and rupture
across a wide spectrum of mouse models.8,10,18,19 Unfortunately, clinical studies on patients with Marfan syndrome have
not mimicked the consistency in mouse models. However,
lack of clear efﬁcacy may be due to the use of losartan, which
is a suboptimal angiotensin receptor antagonist because of its
short half-life and surmountable antagonism. Given the
profound unmet medical needs of patients with thoracic
Journal of the American Heart Association
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decreased TGF-b2, the data were interpreted as being
attributable to increased activity of TGF-b1. This needs to
be tested directly and can now be deﬁned with the availability
of TGF-b1 ﬂoxed mice.
Recently, there have been several aortic studies in mice
where the major TGF-b receptors (TGF-bR) have been either
deleted or modiﬁed to decrease function. These mutations
have primarily focused on TGF-bR1 and R2 that are obligate
heterodimers for TGF-b signaling. Development of adult mice
with deletion of either of the receptors has been hampered by
embryonic lethality. Interestingly, embryonic lethality is
attributed to maldevelopment of thoracic aortic smooth
muscle cells leading to death secondary to aortic rupture.16,17
Currently, there have been 2 major approaches. One was to
develop functional mutants that attenuate TGF-b signaling.18
Mice developed with this approach have reduced ability to
promote TGF-b signaling and have markedly enhanced
expansion of the aorta. A point of controversy in the
interpretation of these data is that while these mutations
decreased TGF-b signaling in cultured cells, they did not
inﬂuence the abundance of pSmad2 in aortas from mice
expressing these mutants. In fact, immunohistochemical
staining of aortic tissue detected increased pSmad2. Another
approach has been to delete TGF-bR2 postnatally in young
adult mice, which has uniformly resulted in an increase of
aortopathies.19–21
In the current issue of JAHA, Dichek and colleagues provide
further conﬁrmation that deletion of TGF-bR2 increases
incidence and severity of aortopathies.5 This is a meticulously
executed study in which the rigorous experimental design is
documented in detail. The experimental design incorporates
many of the issues detailed recently in the National Institutes
of Health requirements for rigor and reproducibility
(https://grants.nih.gov/reproducibility/index.htm), including
randomization and blinding of analysis. Also, the extensively
described statistical approach provides conﬁdence in the
robustness of the conclusions.
This new publication is an extension of a previous study in
which TGF-bR2 was deleted in smooth muscle cells of wildtype mice.21 In this new study, Dichek and colleagues
performed smooth muscle cell–speciﬁc postnatal depletion
of TGF-bR2 in mice that were also haploinsufﬁcient for ﬁbrillin1. This study included an extensive examination of proteins
involved in intracellular signaling when the TGF-b ligand binds
its cell surface receptor. Uniquely, this study determined the
abundance of these signaling proteins prior to the appearance
of overt pathology in ﬁbrillin-1 haploinsufﬁcient mice. Using
this approach, Wei et al5 demonstrated that smooth muscle
cell deletion of TGF-bR2 led to the expected reductions in
pSmad2 abundance. These data contradict other studies of
thoracic aortic aneurysm in ﬁbrillin-1 haploinsufﬁcient mice
that have demonstrated increased pSmad2.22 However, these
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aortic disease, it is imperative to continue efforts to deﬁne the
mechanism and efﬁcacy of drugs that inﬂuence these
pleiotropic molecules.
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